Quality of life assessment after 6 months of initiating treatment with tafamidis in patients with non-Val30Met mutations

Karla Cárdenas-SotoInstituto Nacional de Ciencias Médicas y Nutrición “Salvador Zubirán”, Ciudad de México, Mexico

Benjamín Torres-OctavoInstituto Nacional de Ciencias Médicas y Nutrición “Salvador Zubirán”, Ciudad de México, Mexico

Claudia Mendoza-TejedaInstituto Nacional de Ciencias Médicas y Nutrición “Salvador Zubirán”, Ciudad de México, Mexico

Omar Fueyo-RodríguezInstituto Nacional de Ciencias Médicas y Nutrición “Salvador Zubirán”, Ciudad de México, Mexico

Carolina Domínguez-RicoInstituto Nacional de Ciencias Médicas y Nutrición “Salvador Zubirán”, Ciudad de México, Mexico

Alejandra Gonzalez-DuarteInstituto Nacional de Ciencias Médicas y Nutrición “Salvador Zubirán”, Ciudad de México, Mexico Correspondence[email protected]

References

González-Duarte A, Cárdenas-Soto K, Bañuelos CE, et al. Amyloidosis due to TTR mutations in Mexico with 4 distinct genotypes in the index cases. Orphanet J Rare Dis. 2018;13:107.
PubMed Web of Science ®Google Scholar
Merlini G, Planté-Bordeneuve V, Judge D, at al. Effects of tafamidis on transthyretin stabilization and clinical outcomes in patients with non-Val30Met transthyretin amyloidosis. J Cardiovasc Trans Res. 2013;6:1011–1020.
PubMed Web of Science ®Google Scholar
Wilczek HE, Larsson M, Ericzon BG. Long term data from the Familial Amyloidotic Polyneuropathy World Transplant Registry (FAPWTR). Amyloid. 2011;18:193–195.
PubMed Web of Science ®Google Scholar
Ando Y, Sekijima Y, Obayashi K, et al. Effects of tafamidis treatment on transthyretin (TTR) stabilization, efficacy, and safety in Japanese patients with familial amyloid polyneuropathy (TTR-FAP) with Val30Met and non-Val30Met: A phase III, open label study. J Neurol Sci. 2016;362:266–271.
PubMed Web of Science ®Google Scholar
Vinik EJ, Vinik AI, Paulson JF, et al. Norfolk QOL-DN: validation of a patient reported outcome measure in transthyretin familial amyloid polyneuropathy. J Peripher Nerv Syst. 2014;19:104–114.
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Quality of life assessment after 6 months of initiating treatment with tafamidis in patients with non-Val30Met mutations

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Quality of life assessment after 6 months of initiating treatment with tafamidis in patients with non-Val30Met mutations

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date